<DOC>
	<DOCNO>NCT01645085</DOCNO>
	<brief_summary>A study Healthy Volunteers Compare Amount R406 Blood When Given Different Formulations Fostamatinib .</brief_summary>
	<brief_title>A Study Assess Bioequivalence R406 Healthy Volunteers When Given 100mg 150 mg Fostamatinib</brief_title>
	<detailed_description>An Open-label , Single-center , Randomized , 4-way Crossover Study Assess Bioequivalence R406 Healthy Volunteers 100 150mg Fostamatinib Administered 13 % Drug-loaded Tablet Versus 38 % Drug-loaded Tablet . Treatment sequence determine use two 2-2 crossover design sequence , 1 treatment A B , 1 treatment C D. The order design contain AB/BA CD/DC within overall design , well order treatment within design , randomize . This give total 8 possible treatment sequence follow : ABCD , ABDC , BACD , BADC , CDAB , CDBA , DCAB , DCBA .</detailed_description>
	<mesh_term>Mannitol</mesh_term>
	<criteria>Males nonlactating , non childbearing potential female 18 55 year , inclusive weight least 50 kg BMI 18 30 kg/m2 , inclusive Females must negative pregnancy test screen admission study center period , must lactate must non childbearing potential Non childbearing potential confirm postmenopausal define amenorrhea least 12 month follow cessation exogenous hormonal treatment FSH LH level laboratorydefined postmenopausal range Non childbearing potential confirm documentation irreversible surgical sterilization hysterectomy , bilateral oophorectomy , bilateral salpingectomy tubal ligation . History clinically significant disease disorder , include GI , hepatic renal disease , condition know interfere absorption , distribution , metabolism , excretion drug Any positive result screen serum hepatitis B surface antigen , hepatitis C antibody , human immunodeficiency virus ( HIV ) antibody Known suspected history drug abuse , judge investigator Any clinically significant abnormality 12lead ECG judge Investigator Current smoker , smoke , use nicotinecontaining product , use smoke cessation treatment within previous 1 month prior enrollment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>R406</keyword>
	<keyword>Fostamatinib</keyword>
	<keyword>Phase I</keyword>
	<keyword>Healthy Subjects</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Bioequivalence</keyword>
</DOC>